share_log

HC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $8 Price Target

Benzinga ·  Jun 26, 2023 16:11

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Microbot Medical (NASDAQ:MBOT) with a Buy and maintains $8 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment